Nereus Pharmaceuticals focuses on drug discovery and development derived from marine microbial sources. The company is headquartered in San Diego, CA and concentrates on oncology programs. It currently has two clinical-stage oncology candidates: plinabulin (NPI-2358), a tumor vascular disrupting agent in a Phase 2 trial for non-small cell lung cancer, and a proteasome inhibitor (NPI-0052) in multiple Phase I trials for solid tumors, lymphomas, and multiple myeloma. Nereus recently completed a $20M financing to support the progress of its clinical programs. The financing was provided in conjunction with advancement of those trials, indicating capital is being directed to clinical development. Nereus Pharmaceuticals is a San Diego–based biopharmaceutical company developing cancer therapeutics based on marine microbes. The company focuses on advancing drug candidates through clinical trials. It announced a $45M Series D-2 financing to fund development activities. The funding will be drawn down in two tranches. Proceeds are earmarked to complete Phase I and begin Phase II trials for two of its drug candidates. The round includes both new lead investors and participation from multiple existing backers.

Total raised

$65M

Funding rounds

2

Latest round

Equity

Latest activity

Jun 2010